Critical Development Needs for Recombinant Blood-Coagulation Factors

O. B. Ustinnikova; O. B. Runova; E. V. Novikova; V. P. Bondarev; E. V. Lebedinskaya

doi:10.1007/s11094-016-1492-0

Critical Development Needs for Recombinant Blood-Coagulation Factors

Authors: Ustinnikova O.B.¹, Runova O.B.¹, Novikova E.V.¹, Bondarev V.P.¹, Lebedinskaya E.V.¹
Affiliations:
1. State Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
Issue: Vol 50, No 9 (2016)
Pages: 573-576
Section: Molecular-Biological Problems of Drug Design and Mechanism of Drug Action
URL: https://ogarev-online.ru/0091-150X/article/view/244439
DOI: https://doi.org/10.1007/s11094-016-1492-0
ID: 244439

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Critical development needs for recombinant blood-coagulation factors (RBCFs) are reviewed. The production of less immunogenic drugs with suppressed induction of inhibitory antibodies and prolonged therapeutic effects resulting from an increased inactivation threshold is demonstrated to be a major need for designing new RBCF modifications differing in structure and composition from endogenous blood-coagulation factors while retaining their activity.